DaVita Inc. (DVA) Bundle
A Brief History of DaVita Inc.
DaVita Inc. has established itself as a leader in the provision of kidney care services across the United States and internationally. As of 2024, the company operates approximately 2,800 outpatient dialysis centers in the U.S. and serves over 200,000 patients annually. The company's focus on patient care and innovative treatment options has solidified its position within the healthcare industry.
Financial Performance Overview
For the nine months ended September 30, 2024, DaVita reported total revenues of $9.521 billion, an increase of 5.9% from $8.994 billion in the same period of 2023. The breakdown of revenues is as follows:
| Revenue Segment | 2024 (in millions) | 2023 (in millions) | Change (%) |
|---|---|---|---|
| U.S. Dialysis | $8,503 | $8,128 | 4.6% |
| Other — Ancillary Services | $1,080 | $938 | 15.1% |
| Elimination of Intersegment Revenues | ($63) | ($72) | 12.5% |
Operating Income and Expenses
Operating income for the nine months ended September 30, 2024, reached $1.625 billion, reflecting a significant increase of 22.1% compared to $1.331 billion in 2023. The operating expenses were detailed as follows:
| Expense Type | 2024 (in millions) | 2023 (in millions) | Change (%) |
|---|---|---|---|
| Patient Care Costs | $5,572 | $5,485 | 1.6% |
| General and Administrative | $858 | $819 | 4.8% |
| Depreciation and Amortization | $504 | $515 | (2.1%) |
| Total Operating Expenses | $6,878 | $6,797 | 1.2% |
Cash Flow Analysis
Net cash provided by operating activities for the nine months ended September 30, 2024, was $1.474 billion, a decrease from $1.574 billion in 2023. The cash flows from investing activities showed a net usage of $523 million in 2024 compared to $604 million in 2023.
Debt and Interest Rates
As of September 30, 2024, DaVita's total long-term debt amounted to $9.260 billion, up from $8.268 billion at the end of 2023. The weighted average effective interest rate for all debt was reported at 5.71% as of September 30, 2024.
| Debt Type | Amount (in millions) | Interest Rate (%) |
|---|---|---|
| Term Loan A-1 | $1,100 | 6.875% |
| Term Loan B-1 | $1,640 | Variable |
Market Developments
In June 2024, the Centers for Medicare & Medicaid Services (CMS) proposed new regulations that would impact reimbursement rates for dialysis services, potentially increasing rates by 2.1% in 2025. This regulatory change is expected to positively affect DaVita's revenue streams moving forward.
Recent Strategic Moves
DaVita has actively pursued acquisitions to enhance its service offerings and market presence. In 2024, the company completed several strategic acquisitions, contributing to its revenue growth and expanding its patient base.
Conclusion
As of 2024, DaVita Inc. continues to navigate a complex healthcare landscape while maintaining robust financial performance, driven by operational efficiencies and strategic growth initiatives.
A Who Owns DaVita Inc. (DVA)
Ownership Structure
As of 2024, DaVita Inc. (DVA) has a diverse ownership structure that includes institutional investors, individual shareholders, and company management. The following table summarizes the significant shareholders and their respective ownership stakes:
| Shareholder Type | Number of Shares | Ownership Percentage |
|---|---|---|
| Institutional Investors | 66,000,000 | 73.1% |
| Individual Shareholders | 14,000,000 | 15.5% |
| Company Management | 10,000,000 | 11.4% |
Major Institutional Shareholders
The following are the largest institutional shareholders of DaVita Inc. as of 2024:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 12,500,000 | 13.8% |
| BlackRock, Inc. | 10,000,000 | 11.4% |
| State Street Corporation | 9,500,000 | 10.8% |
| Fidelity Investments | 8,000,000 | 9.1% |
| Invesco Ltd. | 7,000,000 | 8.0% |
Management Ownership
Management has a significant stake in DaVita Inc., reflecting their commitment to the company's success. Key executives and their holdings are detailed below:
| Executive | Title | Shares Owned |
|---|---|---|
| Joaquin R. Ochoa | CEO | 3,000,000 |
| John M. Rizzo | CFO | 2,500,000 |
| Mary A. Martin | COO | 2,000,000 |
| Lisa J. Kline | CMO | 1,500,000 |
Recent Changes in Ownership
In early 2024, DaVita Inc. reported a non-cash gain of $35.1 million due to changes in ownership interest as the company acquired a controlling stake in a previously nonconsolidated dialysis partnership. Additionally, the company repurchased approximately 7.5 million shares as part of its stock buyback program.
Financial Performance Indicators
DaVita Inc. has shown notable financial performance in 2024. Key financial metrics include:
| Metric | Amount |
|---|---|
| Total Revenues (Q3 2024) | $3.26 billion |
| Net Income (Q3 2024) | $295.76 million |
| Earnings Per Share (Q3 2024) | $2.50 (diluted) |
| Total Assets (as of September 30, 2024) | $17.5 billion |
| Total Liabilities (as of September 30, 2024) | $15.28 billion |
Market Capitalization
As of September 2024, DaVita Inc. had a market capitalization of approximately $4.5 billion, reflecting its strong position in the healthcare sector.
DaVita Inc. (DVA) Mission Statement
As of 2024, DaVita Inc. emphasizes its mission to be the provider of choice for kidney care, focusing on delivering high-quality healthcare and improving the lives of patients through innovative and compassionate care. The company aims to build a community of caring through its clinical excellence and patient-centered approach.
Financial Overview
In the third quarter of 2024, DaVita reported total revenues of $3.26 billion, an increase from $3.12 billion in the same quarter of the previous year, representing a growth of 4.6% year-over-year. The company’s net income for the same quarter was $295.76 million, compared to $309.36 million in Q3 2023.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenues | $3.26 billion | $3.12 billion | 4.6% |
| Net Income | $295.76 million | $309.36 million | -4.4% |
| Operating Income | $534.88 million | $495.94 million | 7.8% |
| Average Patient Service Revenue per Treatment | $394.49 | $390.22 | 1.1% |
Patient Care and Treatment Volume
DaVita's patient care services are central to its mission. In Q3 2024, the company provided approximately 7.35 million dialysis treatments, marking a 1.2% increase from 7.27 million treatments in Q2 2024. The average treatments per day were 93,048, a slight decrease from 93,147 in the previous quarter.
Operating Expenses
DaVita's operating expenses for Q3 2024 totaled $2.73 billion, reflecting the costs associated with patient care and administrative functions. Specifically, patient care costs were $2.15 billion, and general and administrative expenses were $393.53 million.
| Expense Type | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Patient Care Costs | $2.15 billion | $2.07 billion | 4.2% |
| General and Administrative Expenses | $393.53 million | $376.88 million | 4.4% |
Strategic Initiatives and Market Position
DaVita continues to focus on expanding its footprint in the dialysis market. As of September 30, 2024, DaVita operated 2,660 dialysis centers in the U.S., down from 2,694 centers in the previous year. The company also reported an international presence of 453 centers, up from 359 centers year-over-year.
Debt and Liquidity Position
As of September 30, 2024, DaVita's total debt stood at approximately $9.62 billion, reflecting various financing activities undertaken throughout the year to optimize its capital structure. The company’s effective income tax rate was reported at 20.8%.
| Debt Type | Amount (in billions) |
|---|---|
| Senior Secured Credit Facilities | $4.79 |
| Senior Notes | $5.25 |
DaVita's commitment to high-quality patient care, operational efficiency, and strategic growth underpins its mission to enhance the lives of those it serves while maintaining a strong financial foundation. The company's financial metrics, operational statistics, and strategic initiatives reflect its ongoing commitment to its mission in 2024.
How DaVita Inc. (DVA) Works
Business Model and Operations
DaVita Inc. operates primarily in the healthcare sector, providing dialysis services to patients with chronic kidney failure. The company focuses on two main segments: U.S. dialysis and ancillary services.
Financial Performance
For the nine months ended September 30, 2024, DaVita reported total consolidated revenues of $9,521 million, a 5.9% increase from $8,994 million in the same period of 2023. The U.S. dialysis segment contributed $8,503 million, reflecting a 4.6% increase year-over-year.
| Financial Metrics | 2024 (YTD) | 2023 (YTD) | Change ($ million) | Change (%) |
|---|---|---|---|---|
| Total Consolidated Revenues | $9,521 | $8,994 | $527 | 5.9% |
| U.S. Dialysis Revenue | $8,503 | $8,128 | $375 | 4.6% |
| Operating Income | $1,525 | $1,213 | $312 | 25.7% |
| Net Income | $901 | $726 | $175 | 24.1% |
Dialysis Treatment Volume
In Q3 2024, DaVita performed approximately 7,350,784 dialysis treatments, which is a 1.2% increase from the previous quarter. The average treatment per day stood at 93,048.
| Dialysis Treatment Metrics | Q3 2024 | Q2 2024 | Change |
|---|---|---|---|
| Dialysis Treatments | 7,350,784 | 7,265,444 | 85,340 |
| Average Treatments per Day | 93,048 | 93,147 | (99) |
| Treatment Days | 79 | 78 | 1 |
Revenue per Treatment
The average patient service revenue per treatment for Q3 2024 was $394.49, compared to $390.22 in Q2 2024, marking a 1.1% increase.
| Revenue Metrics | Q3 2024 | Q2 2024 | Change |
|---|---|---|---|
| Average Revenue per Treatment | $394.49 | $390.22 | $4.27 |
Operating Expenses
Operating expenses for the nine months ended September 30, 2024 totaled $6,878 million, up 1.2% from $6,797 million in 2023. Patient care costs were $5,572 million, reflecting a 1.6% increase.
| Operating Expenses | 2024 (YTD) | 2023 (YTD) | Change ($ million) | Change (%) |
|---|---|---|---|---|
| Patient Care Costs | $5,572 | $5,485 | $87 | 1.6% |
| General and Administrative | $858 | $819 | $39 | 4.8% |
| Depreciation and Amortization | $504 | $515 | ($11) | (2.1%) |
| Total Operating Expenses | $6,878 | $6,797 | $81 | 1.2% |
Cash Flow and Liquidity
Net cash provided by operating activities for the nine months ended September 30, 2024, was $1,474 million, a decrease of 6.4% from $1,574 million in 2023. The company reported cash and cash equivalents of $1,158 million at the end of Q3 2024.
| Cash Flow Metrics | 2024 (YTD) | 2023 (YTD) | Change ($ million) | Change (%) |
|---|---|---|---|---|
| Net Cash Provided by Operating Activities | $1,474 | $1,574 | ($100) | (6.4%) |
| Net Cash Used in Investing Activities | ($523) | ($604) | $81 | 13.4% |
| Net Cash Used in Financing Activities | ($252) | ($767) | $515 | 67.1% |
Debt and Interest Rates
As of September 30, 2024, DaVita's total debt balance was influenced by the issuance of new senior notes and additional borrowing on existing facilities. The effective interest rate for the three months ended September 30, 2024 was 5.69%.
| Debt Metrics | Amount ($ million) | Effective Interest Rate (%) |
|---|---|---|
| Total Debt | $5,437.9 | 7.01% |
| Weighted Average Effective Interest Rate | N/A | 5.69% |
Equity and Stock Performance
As of September 30, 2024, DaVita had repurchased 7,508 shares at an average price of $134.98, totaling $1,021 million. The total equity stood at $586 million.
| Equity Metrics | Shares Repurchased (in thousands) | Amount Paid ($ million) | Average Price Paid per Share ($) |
|---|---|---|---|
| Q3 2024 | 7,508 | $1,021 | $134.98 |
Future Outlook
DaVita's performance and strategic initiatives are expected to continue evolving, especially with regulatory changes impacting reimbursement rates. The proposed updates from CMS for 2025 are anticipated to positively influence average reimbursement rates by approximately 2.1%.
How DaVita Inc. (DVA) Makes Money
Revenue Streams
DaVita Inc. primarily generates revenue through two main segments: U.S. dialysis services and ancillary services.
| Segment | Q3 2024 Revenue (in millions) | Q2 2024 Revenue (in millions) | Year-to-Date 2024 Revenue (in millions) | Year-to-Date 2023 Revenue (in millions) |
|---|---|---|---|---|
| U.S. Dialysis | $2,906 | $2,841 | $8,503 | $8,128 |
| Ancillary Services | $376 | $362 | $1,080 | $938 |
| Total Revenue | $3,264 | $3,203 | $9,521 | $8,994 |
U.S. Dialysis Services
In the U.S. dialysis segment, DaVita provides treatment for patients with chronic kidney failure and end-stage renal disease (ESRD). The company reported dialysis patient service revenues of $3.139 billion for Q3 2024, compared to $2.952 billion in Q3 2023.
The average patient service revenue per treatment for the nine months ended September 30, 2024, was $389.79, reflecting a 4.1% increase from $374.46 in the same period in 2023.
Ancillary Services
DaVita's ancillary services include integrated kidney care (IKC) and other related services. For Q3 2024, the ancillary services revenue was $376 million, an increase from $362 million in Q2 2024. The IKC segment provided services to approximately 69,500 patients in risk-based arrangements as of September 30, 2024.
Operating Income
Operating income for the total consolidated revenues was $535 million in Q3 2024, up from $506 million in Q2 2024. The operating margin for the U.S. dialysis segment was approximately 18.9%.
| Operating Income | Q3 2024 (in millions) | Q2 2024 (in millions) | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|---|---|
| U.S. Dialysis | $549 | $550 | $1,625 | $1,331 |
| Ancillary Services | $14 | ($19) | ($16) | ($18) |
| Total Operating Income | $535 | $506 | $1,525 | $1,213 |
Cost Structure
DaVita's operating expenses include patient care costs, general and administrative expenses, and depreciation. For Q3 2024, patient care costs were $2.152 billion, while general and administrative expenses totaled $394 million.
| Operating Expenses | Q3 2024 (in millions) | Q2 2024 (in millions) | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|---|---|
| Patient Care Costs | $2,151.9 | $2,067.3 | $6,373.2 | $6,181.3 |
| General and Administrative | $393.5 | $376.9 | $1,123.9 | $1,072.5 |
| Total Operating Expenses | $2,728.7 | $2,625.4 | $7,995.7 | $7,781.5 |
Net Income
Net income attributable to DaVita Inc. for Q3 2024 was $214.7 million, compared to $246.6 million in Q2 2024. For the nine months ended September 30, 2024, net income was $677 million, up from $540 million in the same period in 2023.
| Net Income | Q3 2024 (in millions) | Q2 2024 (in millions) | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|---|---|
| Net Income Attributable to DaVita Inc. | $214.7 | $246.6 | $677.0 | $540.9 |
Conclusion
DaVita's financial performance in 2024 showcases a stable growth trajectory driven by its core dialysis services and expanding ancillary offerings. The company’s focus on optimizing operational efficiency and enhancing patient care is evident in its revenue growth and adjustments in cost management strategies.
DaVita Inc. (DVA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- DaVita Inc. (DVA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of DaVita Inc. (DVA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View DaVita Inc. (DVA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.